Sanofi annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanofi Return on Equity (ROE) Growth & History (SAN)
Sanofi's return on equity was 10.55% for fiscal 2025.
View full Sanofi company overviewSanofi annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 10.55% | +3.13 pp |
| 2024 | 2024-12-31 | 7.41% | +0.11 pp |
| 2023 | 2023-12-31 | 7.31% | −4.52 pp |
| 2022 | 2022-12-31 | 11.83% | +2.30 pp |
| 2021 | 2021-12-31 | 9.53% | −10.66 pp |
| 2020 | 2020-12-31 | 20.19% | +15.46 pp |
| 2019 | 2019-12-31 | 4.72% | −2.82 pp |
| 2018 | 2018-12-31 | 7.54% | −7.23 pp |
| 2017 | 2017-12-31 | 14.77% | +6.46 pp |
| 2016 | 2016-12-31 | 8.30% | — |
Sanofi quarterly return on equity
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.48% | −4.86 pp |
| Q1 2026 | 2026-03-31 | 2.24% | — |
| Q4 2025 | 2025-12-31 | −1.11% | — |
| Q3 2025 | 2025-09-30 | 3.91% | — |
| Q2 2025 | 2025-06-30 | 5.34% | — |
Sanofi return on equity trends
Over the last five fiscal years, Sanofi's return on equity decreased from 20.19% to 10.55%, a change of −9.64 percentage points. The latest reported quarter, Q2 2026, shows 0.48%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanofi source filings ↗